AFM
IMRX icon

Anson Funds Management’s Immuneering IMRX Stock Holding History

Anson Funds Management’s Portfolio IMRX Stock Details IMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-32,603
Closed -$158K – 195
2022
Q4 		$158K Buy
+32,603
New +$289K 0.03% 205

Other funds holding IMRX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $123B AUM 34.51% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

Anson Funds Management's IMRX Position: Q1 2023 in Review

Anson Funds Management sold out of Immuneering (IMRX) in Q1 2023, closing a stake of 32,603 shares — an estimated $158K sold.

Anson Funds Management first reported a position in IMRX in Q4 2022 and held it in 1 quarter. The position peaked at $158K in Q4 2022. 34 funds tracked by Wall St. Rank hold IMRX as of Q1 2023.

  • Anson Funds Management reported no remaining Immuneering position as of Q1 2023 after selling out during the quarter.
  • Anson Funds Management sold 32,603 Immuneering shares in Q1 2023, an estimated $158K.
  • Anson Funds Management first reported a position in Immuneering in Q4 2022 and held it in 1 quarter.
  • Anson Funds Management's Immuneering position peaked at $158K in Q4 2022.
  • 34 funds tracked by Wall St. Rank held Immuneering as of Q1 2023.

Based on Anson Funds Management's 13F filing for Q1 2023, filed 15 May 2023.